drugset
Drugs / mixed amphetamine salts-extended release
last change Jul 2025 re-read 2 minutes ago

mixed amphetamine salts-extended release

also known as MAS XR · MAS-ER
Developed for
attention deficit-hyperactivity disorder · cocaine dependence
Investigated by
Boston Children's Hospital · National Institute of Mental Health (NIMH) · National Institute on Drug Abuse (NIDA) · New York State Psychiatric Institute · Seattle Children's Hospital · Shire
+2 more · Tris Pharma, Inc. · University of Cincinnati

Trials 4 · a red edge is where a trial was stopped

today NCT07650643 · Ph 4 NCT02478788 · Ph 4 NCT01986075 · Ph 1/2 NCT00557960 · Ph 3
20042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT01986075 Jan 2014 → Jan 2021 cocaine dependence New York State Psychiatric Institute Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00557960 Feb → Oct 2004 attention deficit-hyperactivity disorder Shire Completed No outcome recorded
Phase 42 trials
Phase 4 NCT07650643 Sep 2026 → May 2031 expected attention deficit-hyperactivity disorder Boston Children's Hospital Not yet recruiting No outcome recorded
Phase 4 NCT02478788 Nov 2015 → Aug 2022 attention deficit-hyperactivity disorder University of Cincinnati Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as mixed amphetamine salts-extended release “This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts-extended release (MAS XR 50 mg/day (Cohort 1)” PMID 18815438 ↗ Sep 2008
4

“Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine.” PMID 18815438 ↗ Sep 2008

NCT01986075 ↗

NCT07650643 ↗

NCT02478788 ↗
Known as MAS XR “This study investigated the effects of 12-week mixed amphetamine salts-extended release (MAS-XR) treatment on brain functional networks and symptom changes in ADHD youth with...” PMID 40712681 ↗ Jul 2025
1

“This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts-extended release (MAS XR 50 mg/day (Cohort 1)” PMID 18815438 ↗ Sep 2008
Known as MAS-ER “80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT” NCT01986075 ↗